Accolade is an employer healthcare navigation and benefits platform that helps employees understand and navigate complex healthcare benefits, reducing costs and improving outcomes. The company provides personalized healthcare advocacy, second opinions, virtual primary care, and mental health support services. Accolade served over 20 million members across 1,700+ employer and health plan clients before its acquisition by Transcarent in 2025.
Accolade is publicly traded
IPO'd on July 2, 2020
This company is no longer available on our private secondary market. Shares can be traded publicly under ACCD.
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2007
Employees
500+
Total Funding
$381.1M
8 rounds
Last Private Valuation
$1.2B
July 2, 2020
Total raised $381.1M across 8 rounds
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Last updated 06-25-2026
Latest Round
Type
IPO
Date
July 2, 2020
Amount
$220M
Valuation
$1.2B
Lead Investors
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| July 2, 2020 | IPO | $220M | $1.2B | Public markets |
| 2019 | Corporate | $20M | — | Humana |
| 2018 | Series F | $50M | — | Andreessen Horowitz, Carrick Capital Partners, Madrona Venture Group +1 more |
Rajeev Singh
CEO (2015-2025)
Tom Spann
Co-founder, Vice Chairman
J Michael Cline
Co-founder
Competitor list is illustrative and may be incomplete, stale, or erroneous.
Quantum Health
Healthcare advocacy and navigation platform
Teladoc Health
Digital health and telehealth platform (acquired Livongo)
Amino Health
AI-powered healthcare navigation platform
Goldfinch Health
Healthcare navigation and advocacy
Grand Rounds
Digital health navigation platform
Castlight Health
Healthcare navigation and cost transparency platform
Yes, Accolade is publicly traded under the ticker symbol ACCD on the NASDAQ. The company went public in July 2, 2020.
Accolade trades under the ticker symbol ACCD on the NASDAQ. It began trading in July 2, 2020.
Accolade (ACCD on the NASDAQ) shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker ACCD to place an order.
Accolade went public in July 2, 2020 via ipo, with an offering valuation of approximately $1.2B. Accolade went public on Nasdaq (ACCD) in July 2020 at a $1.2B post-money valuation, raising $220M. The company was taken private by digital health startup Transcarent in a $621 million acquisition announced in January 2025 and completed on April 8, 2025. Shareholders received $7.03 per share in cash, representing a 110% premium to the closing price on January 7, 2025. Accolade's stock was delisted from Nasdaq upon completion of the merger.
Accolade raised $381.1M across 8 disclosed funding rounds prior to its public listing.
Accolade was co-founded by Tom Spann, and J Michael Cline in 2007.
Accolade is headquartered in Plymouth Meeting, PA.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.